Evolution of novel, orally efficacious renin inhibitors: A topographical design approach towards Aliskiren.

被引：0
|
作者：
Maibaum, J [1 ]
机构：
[1] Novartis Pharma AG, Novartis Inst Biomed Res Basel, CH-4002 Basel, Switzerland
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2003年 / 226卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
50-MEDI
引用
收藏
页码：U9 / U9
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE MODELING OF PROTEINS IN THE DESIGN OF NOVEL RENIN INHIBITORS
    GREER, J
    BIOPHYSICAL JOURNAL, 1990, 57 (02) : A207 - A207
  • [22] COMPARATIVE MODELING OF PROTEINS IN THE DESIGN OF NOVEL RENIN INHIBITORS
    HUTCHINS, C
    GREER, J
    CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1991, 26 (01) : 77 - 127
  • [23] Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers.
    Dieterich, H
    Kemp, C
    Vaidyanathan, S
    Yeh, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P64 - P64
  • [24] DESIGN AND SYNTHESIS OF POTENT, SELECTIVE, AND ORALLY ACTIVE FLUORINE-CONTAINING RENIN INHIBITORS
    DOHERTY, AM
    SIRCAR, I
    KORNBERG, BE
    QUIN, J
    WINTERS, RT
    KALTENBRONN, JS
    TAYLOR, MD
    BATLEY, BL
    RAPUNDALO, SR
    RYAN, MJ
    PAINCHAUD, CA
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (01) : 2 - 14
  • [25] Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A
    Burdi, Douglas F.
    Campbell, John E.
    Wang, Jun
    Zhao, Sufang
    Zhong, Hua
    Wei, Jianfeng
    Campbell, Una
    Shao, Liming
    Herman, Lee
    Koch, Patrick
    Jones, Philip G.
    Hewitt, Michael C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (09) : 1864 - 1868
  • [26] Towards an approach for novel design
    Ozkan, N
    Paris, C
    Simpson-Young, B
    OZCHI 98 - 1998 AUSTRALASIAN COMPUTER HUMAN INTERACTION CONFERENCE, PROCEEDINGS, 1998, : 186 - 191
  • [27] Design and synthesis of a novel orally efficacious PAI-1 inhibitor for the treatment of fibrinolytic impairment
    Mayer, Scott C.
    Antrilli, Thomas
    Aulabaugh, Ann
    Butera, John A.
    Crandall, David L.
    Elokdah, Hassan
    Gardell, Stephen
    Gundersen, Eric
    Hennan, James
    Krishnamurthy, Girija
    McFarlane, Geraldine R.
    Morgan, Gwen
    Swillo, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [28] A Multivalent Approach to the Design and Discovery of Orally Efficacious 5-HT4 Receptor Agonists
    McKinnell, R. Murray
    Armstrong, Scott R.
    Beattie, David T.
    Choi, Seok-Ki
    Fatheree, Paul R.
    Gendron, Roland A. L.
    Goldblum, Adam
    Humphrey, Patrick P.
    Long, Daniel D.
    Marquess, Daniel G.
    Shaw, J. P.
    Smith, Jacqueline A. M.
    Turner, S. Derek
    Vickery, Ross G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (17) : 5330 - 5343
  • [29] The design, synthesis and evaluation of 2-aminobenzoxazole analogues as potent and orally efficacious ChemR23 inhibitors
    Imaizumi, Takamichi
    Otsubo, Shigeki
    Komai, Masato
    Takada, Hidenori
    Maemoto, Michihiro
    Kobayashi, Atsuko
    Otsubo, Nobumasa
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (17)
  • [30] Design of a novel class of small non-peptide delta-amino hydroxyethylene isosteres as potent and orally active renin inhibitors
    Rasetti, V
    Maibaum, J
    Rueger, H
    Cohen, NC
    Goschke, R
    Mah, R
    Rahuel, J
    Cumin, F
    Grutter, M
    Fuhrer, W
    Wood, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 14 - MEDI
12345